More information: Insung Park et al, Orexin receptor antagonist increases fat oxidation and suppresses protein catabolism during sleep in humans, iScience (2024). DOI: 10.1016/j.isci.2024.110212 ...

For most of us, getting less than seven hours of sleep translates into grogginess, sluggish thinking, and an overwhelming ...

Orexin antagonists, meanwhile – such as Eisai's Dayvigo (lemborexant), Merck & Co's Belsomra (suvorexant) and Idorsia's recently filed daridorexant – have proved effective as treatments for ...

Daridorexant is a potential best-in-class treatment in the high-growth, dual orexin antagonist class of medicines treating ...

For 2025, Alkermes plans to generate over $200 million in EBITDA while advancing its orexin program, particularly ALKS 2680, which is enrolling Phase 2 studies for narcolepsy. These studies are ...

NLS Pharmaceutics (NLSP) announces new preclinical findings on AEX-2, reinforcing its potential as a first-in-class non-sulfonamide dual orexin ...

Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia in the dual orexin receptor antagonist class, ahead of rival drugs from Merck & Co and Eisai.

The two major types of narcolepsy are: Narcolepsy type 1. People with type 1 narcolepsy have low levels of orexin (hypocretin), a brain chemical that regulates wakefulness. Damage to the brain ...

Bial-Portela & Ca SA has identified orexin OX1 receptor antagonists reported to be useful for the treatment of cognitive, sleep, anxiety and eating disorders, depression, obesity, schizophrenia, ...

NLS Pharmaceutics Ltd., in collaboration with Aexon Labs Inc., has announced new preclinical findings on AEX-2, a non-sulfonamide dual orexin receptor agonist (DOXA) with potential for narcolepsy and ...

The companies highlighted AEX-2's ability to enhance wakefulness, preserve REM sleep, and reduce cataplexy in orexin-deficient mouse models. With a current ratio of 0.15, indicating potential ...

Nxera Pharma inks agreement with Holling Bio-Pharma to commercialize daridorexant in Taiwan: Tokyo, Japan Monday, March 3, 2025, 16:00 Hrs [IST] Nxera Pharma Co., Ltd. announces t ...